The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Cardiovascular and Cerebrovascular Comorbidities of Hypokalemic and Normokalemic Primary Aldosteronism: Results of the German Conn’s Registry
Abstract
CONTEXT: Primary aldosteronism (PA) is associated with vascular end-organ damage. OBJECTIVE: Our objective was to evaluate differences regarding comorbidities between the hypokalemic and normokalemic form of PA. DESIGN AND SETTING: This was a retrospective cross-sectional study collected from six German centers (German Conn's registry) between 1990 and 2007. PATIENTS: Of 640 registered patients with PA, 553 patients were analyzed. MAIN OUTCOME MEASURES: Comorbidities depending on hypokalemia or normokalemia were examined. RESULTS: Of the 553 patients (61 +/- 13 yr, range 13-96), 56.1% had hypokalemic PA. The systolic (164 +/- 29 vs. 155 +/- 27 mm Hg; P < 0.01) and diastolic (96 +/- 18 vs. 93 +/- 15 mm Hg; P < 0.05) blood pressures were significantly higher in hypokalemic patients than in those with the normokalemic variant. The prevalence of cardiovascular events (angina pectoris, myocardial infarction, chronic cardiac insufficiency, coronary angioplasty) was 16.3%. Atrial fibrillation occurred in 7.1% and other atrial or ventricular arrhythmia in 5.2% of the patients. Angina pectoris and chronic cardiac insufficiency were significantly more prevalent in hypokalemic PA (9.0 vs. 2.1%, P < 0.001; 5.5 vs. 2.1%, P < 0.01). Overall, cerebrovascular comorbidities were not different between hypokalemic and normokalemic patients, however, stroke tended to be more prevalent in normokalemic patients. CONCLUSIONS: Our data indicate a high prevalence of comorbidities in patients with PA. The hypokalemic variant is defined by a higher morbidity than the normokalemic variant regarding some cardiovascular but not cerebrovascular events. Thus, PA should be sought not only in hypokalemic but also in normokalemic hypertensives because high-excess morbidity occurs in both subgroups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Global burden of blood-pressure-related disease, 2001
Lawes, C. M., Hoorn, S. V., & Rodgers, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60655-8 · Cited by 2,330
Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism
Milliez, P., Girerd, X., Plouin, P.-F., Blacher, J., Safar, M. E., & Mourad, J.-J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.015 · Cited by 1,547
A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients
Rossi, G. P., Bernini, G., Caliumi, C., Desideri, G., Fabris, B., Ferri, C., Ganzaroli, C., Giacchetti, G., Letizia, C., Maccario, M., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.059 · Cited by 1,467
Mulatero (2004) · doi:10.1210/jc.2003-031337 · Cited by 961
Pitt, B., Reichek, N., Willenbrock, R., Zannad, F., Phillips, R. A., Roniker, B., Kleiman, J., Krause, S., Burns, D., & Williams, G. H. (2003) · Circulation · doi:10.1161/01.cir.0000091405.00772.6e · Cited by 623
Cardiovascular Outcomes in Patients With Primary Aldosteronism After Treatment
Catena, C. (2008) · Archives of Internal Medicine · doi:10.1001/archinternmed.2007.33 · Cited by 565
HIGH INCIDENCE OF PRIMARY ALDOSTERONISM IN 199 PATIENTS REFERRED WITH HYPERTENSION
Gordon, R. D., Stowasser, M., Tunny, T. J., Klemm, S. A., & Rutherford, J. C. (1994) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1994.tb02519.x · Cited by 496
Mineralocorticoid Blockade Reduces Vascular Injury in Stroke-Prone Hypertensive Rats
Rocha, R., Chander, P. N., Khanna, K., Zuckerman, A., & Stier, C. T. (1998) · Hypertension · doi:10.1161/01.hyp.31.1.451 · Cited by 496
Renal Damage in Primary Aldosteronism: Results of the PAPY Study
Rossi, G. P., Bernini, G., Desideri, G., Fabris, B., Ferri, C., Giacchetti, G., Letizia, C., Maccario, M., Mannelli, M., Matterello, M.-J., et al. (2006) · Hypertension · doi:10.1161/01.hyp.0000230444.01215.6a · Cited by 470
Fardella, C. E., Mosso, L., Gómez-Sánchez, C., Cortés, P., Soto, J., Gómez, L., Pinto, M., Huete, A., Oestreicher, E., Foradori, A., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.5.6596 · Cited by 463
Clinical characteristics of primary aldosteronism from an analysis of 145 cases
Conn, J. W., Knopf, R. F., & Nesbit, R. M. (1964) · The American Journal of Surgery · doi:10.1016/0002-9610(64)90252-1 · Cited by 429
Long-term Renal Outcomes in Patients With Primary Aldosteronism
Sechi, L. A., Novello, M., Lapenna, R., Baroselli, S., Nadalini, E., Colussi, G. L., & Catena, C. (2006) · JAMA · doi:10.1001/jama.295.22.2638 · Cited by 388
Prevalence and Characteristics of the Metabolic Syndrome in Primary Aldosteronism
Fallo, F., Veglio, F., Bertello, C., Sonino, N., Della Mea, P., Ermani, M., Rabbia, F., Federspil, G., & Mulatero, P. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1733 · Cited by 372 · cited 1×
“In addition, recent data have suggested that higher rates of cardiovascular events in PA might be due to an increased prevalence of the metabolic syndrome in PA (34).”
BackgroundCatena, C., Colussi, G., Lapenna, R., Nadalini, E., Chiuch, A., Gianfagna, P., & Sechi, L. A. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.095448 · Cited by 358
Prevalence of Primary Aldosteronism among Asian Hypertensive Patients in Singapore1
Loh, K.-C., Koay, E. S., Khaw, M.-C., Emmanuel, S. C., & Young, W. F. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6752 · Cited by 345
Pratt-Ubunama, M. N., Nishizaka, M. K., Boedefeld, R. L., Cofield, S. S., Harding, S. M., & Calhoun, D. A. (2007) · Chest · doi:10.1378/chest.06-1442 · Cited by 331
Changes in Left Ventricular Anatomy and Function in Hypertension and Primary Aldosteronism
Rossi, G. P., Sacchetto, A., Visentin, P., Canali, C., Graniero, G. R., Palatini, P., & Pessina, A. C. (1996) · Hypertension · doi:10.1161/01.hyp.27.5.1039 · Cited by 328
Aldosterone and end-organ damage
Brown, N. J. (2005) · Current Opinion in Nephrology and Hypertension · doi:10.1097/01.mnh.0000165889.60254.98 · Cited by 320
Fardella, C. E. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.5.1863 · Cited by 298
Low-renin status in therapy-resistant hypertension: a clue to efficient treatment
Eide, I. K., Torjesen, P. A., Drolsum, A., Babovic, A., & Lilledahl, N. P. (2004) · Journal of Hypertension · doi:10.1097/00004872-200411000-00026 · Cited by 265
Aldosterone Excretion Among Subjects With Resistant Hypertension and Symptoms of Sleep Apnea
Calhoun, D. A., Nishizaka, M. K., Zaman, M. A., & Harding, S. M. (2004) · Chest · doi:10.1378/chest.125.1.112 · Cited by 260
Aldosterone and end-organ damage
Marney, A. M., & Brown, N. J. (2007) · Clinical Science · doi:10.1042/cs20070123 · Cited by 212
Pathophysiological effects of aldosterone in cardiovascular tissues
Rocha, R., & Stier, C. T. (2001) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(01)00432-5 · Cited by 212
Primary aldosteronism: cardiovascular, renal and metabolic implications
Rossi, G.-P., Sechi, L. A., Giacchetti, G., Ronconi, V., Strazzullo, P., & Funder, J. W. (2008) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2008.01.006 · Cited by 204
Prevalence of Primary Aldosteronism among Asian Hypertensive Patients in Singapore
Loh, K.-C. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.8.2854 · Cited by 179
Mulatero, P., Bertello, C., Rossato, D., Mengozzi, G., Milan, A., Garrone, C., Giraudo, G., Passarino, G., Garabello, D., Verhovez, A., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2055 · Cited by 178
Cardiovascular complications in patients with primary aldosteronism
Nishimura, M., Uzu, T., Fujii, T., Kuroda, S., Nakamura, S., Inenaga, T., & Kimura, G. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70298-2 · Cited by 160
Is There an Unrecognized Epidemic of Primary Aldosteronism? (Pro)
Calhoun, D. A. (2007) · Hypertension · doi:10.1161/hypertensionaha.106.086116 · Cited by 149
Takeda, R., Matsubara, T., Miyamori, I., Hatakeyama, H., & Morise, T. (1995) · Journal of Endocrinological Investigation · doi:10.1007/bf03347840 · Cited by 132
Left Ventricular Hypertrophy Precedes Other Target-Organ Damage in Primary Aldosteronism
Shigematsu, Y., Hamada, M., Okayama, H., Hara, Y., Hayashi, Y., Kodama, K., Kohara, K., & Hiwada, K. (1997) · Hypertension · doi:10.1161/01.hyp.29.3.723 · Cited by 102
Stowasser, M., & Gordon, R. D. (2001) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00097-8 · Cited by 101
The aldosterone/renin ratio as a screening test for primary aldosteronism.
Rayner, B. L., Opie, L. H., & Davidson, J. S. (2000) · PubMed · Cited by 95
Rizzoni, D., Paiardi, S., Rodella, L. F., Porteri, E., Ciuceis, C. D., Rezzani, R., Boari, G. E. M., Zani, F., Miclini, M., Tiberio, G. A. M., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0101 · Cited by 88
Suzuki, T., Abe, H., Nagata, S., Saitoh, F., Iwata, S., Ashizawa, A., Kuramochi, M., & Omae, T. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)90264-0 · Cited by 51
Ventricular fibrillation: an extreme presentation of primary hyperaldosteronism.
Abdo, A., Bebb, R. A., & Wilkins, G. E. (1999) · PubMed · Cited by 29
Conn's syndrome and atrial fibrillation
Porodko, M., Auer, J., & Eber, B. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04439-1 · Cited by 14
Cited by
Clase, C. M., Carrero, J.-J., Ellison, D. H., Grams, M. E., Hemmelgarn, B. R., Jardine, M. J., Kovesdy, C. P., Kline, G. A., Lindner, G., Obrador, G. T., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.09.018 · Cited by 498
Savard, S., Amar, L., Plouin, P.-F., & Steichen, O. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.01060 · Cited by 505
Long-Term Cardio- and Cerebrovascular Events in Patients With Primary Aldosteronism
Mulatero, P., Monticone, S., Bertello, C., Viola, A., Tizzani, D., Iannaccone, A., Crudo, V., Burrello, J., Milan, A., Rabbia, F., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2805 · Cited by 415
Käyser, S. C., Dekkers, T., Groenewoud, H. J., van der Wilt, G. J., Carel Bakx, J., van der Wel, M. C., Hermus, A. R., Lenders, J. W., & Deinum, J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1472 · Cited by 398
Muñoz-Durango, N., Fuentes, C., Castillo, A., González-Gómez, L., Vecchiola, A., Fardella, C., & Kalergis, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17070797 · Cited by 282
Metadata
- Authors
- Born-Frontsberg, E., Reincke, M., Rump, L. C., Hahner, S., Diederich, S., Lorenz, R., Allolio, B., Seufert, J., Schirpenbach, C., Beuschlein, F., Bidlingmaier, M., Endres, S., Quinkler, M., & for the participants of the German Conn’s Registry
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2009-04-01
- Volume
- 94
- Issue
- 4
- Pages
- 1125-1130
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1976246655
- Cited by
- 261
- References
- 38
- FWCI
- 10.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.